Signature STt O — Comprehensive profiling from a tumour block.
When tissue is available, it can offer high tumour content and a rich, direct read of your cancer's biology.
Signature STt O is our comprehensive genomic profile performed directly on tumour tissue — a formalin-fixed, paraffin-embedded (FFPE) block or slides. When tissue is available, it can offer high tumour content and a rich, direct read of the cancer's biology.
Comprehensive profiling from your tumour block
Full immune profile, PGx, mutational signatures, and the complete Blueprint Care report — signed by KPCIRC.
- Comprehensive gene coverage: SNVs, InDels, fusions, copy-number
- Full immune profile: TMB, MSI, MMR
- Mutational signatures: COSMIC-style analysis
- PGx panel: 35-gene pharmacogenomics profile
- Complete Blueprint Care report: Signed by KPCIRC
Three reasons to choose tissue profiling.
STt O is the right choice when a good tissue block already exists and you want a comprehensive profile from that sample.
Existing FFPE Block
A recent, representative FFPE block already exists from surgery or biopsy. We can profile it without any new procedure.
Low Tumour Shedding
A tumour sheds little DNA into blood, making liquid biopsy less informative. Tissue gives you a direct, high-content read.
Primary Source Preferred
Your team wants a tissue-based comprehensive profile as the primary source for treatment decisions.
Complete. Comprehensive. From tissue.
Everything you need for a comprehensive profile — from your tumour block.
Comprehensive Gene Coverage
SNVs, InDels, fusions and copy-number variation — the complete picture from your tumour tissue.
Full Immune Profile
TMB, MSI, MMR — the complete set, analytically robust for immunotherapy decision-making.
Mutational Signatures
COSMIC-style signatures — what has been driving the mutations in your cancer.
Pharmacogenomics (PGx)
The 35-gene Pharmacogenomics & Drug-Response Panel — how you metabolise key drugs.
All Six Intelligence Layers
Clonal architecture, synergy, subtype, immune readiness, trial matching, and access — fully populated.
Choose the right sample for your situation.
Both tissue and blood have strengths. Here is how they compare.
| Tissue (STt O) | Blood (STb / O / O+) | |
|---|---|---|
| Sample | Existing FFPE block/slides | Simple blood draw |
| Invasiveness | Uses tissue already taken | Non-invasive; repeatable |
| Tumour content | Often high | Depends on DNA shedding |
| Repeat testing | Needs a new sample | Easy to repeat over time |
| Best when | A good block exists | Surgery is difficult, or monitoring is planned |
What we need from your tissue.
An adequate, representative FFPE block with sufficient tumour content is required. Our team advises on suitability before you commit.
Sample Quality
An adequate, representative FFPE block (or a defined number of slides) with sufficient tumour content is required. Our team assesses suitability before you commit.
Tumour Heterogeneity
Tissue results reflect the sampled region of a tumour, which can be heterogeneous. This is one reason blood-based monitoring is a valuable complement.
A full Blueprint Care report.
A full Blueprint Care report — decision, contraindications, trials, biosimilars, resistance plan, and access — signed by KPCIRC, with a regional-language summary and navigator support.
Confirmed at consultation.
Confirmed at consultation, after we check sample suitability.
The words you will see, in plain language.
What we DO
- Profile a tumour block comprehensively, with immune & PGx profile
- Report mutational signatures and copy-number changes
- Feed a complete, MTB-signed Blueprint Care report
- Advise on sample suitability before you commit
What we DON'T do
- Diagnose or decide treatment on its own
- Overcome tumour heterogeneity from one sampled region
- Proceed without an adequate FFPE sample
- Guarantee drug availability, approval, cover, or benefit
Signature STt O is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →